Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Real Time MRI Fused to Cone Beam CT Guided Biopsies of the Prostate.

Not Applicable

Conditions: Prostate Cancer

Interventions: Procedure: CT Fusion + Transrectal U/S Guided Prostate Biopsy

First Posted Date: 2019-11-27

Last Posted Date: 2019-12-04

Lead Sponsor: Queen's University

Target Recruit Count: 20

Registration Number: NCT04180592

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: CFI-400945
Drug: Durvalumab

First Posted Date: 2019-11-25

Last Posted Date: 2024-08-09

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 15

Registration Number: NCT04176848

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 2 locations

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Early Phase 1

Recruiting

Conditions: Lymphoma, B-Cell

Interventions: Drug: Rituximab Injection
Drug: Tafasitamab
Drug: Venetoclax
Drug: Rituximab SC
Drug: Gemcitabine
Drug: Cisplatin
Drug: Dexamethasone
Drug: Glofitamab

First Posted Date: 2019-11-13

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 18

Registration Number: NCT04161248

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
The Jewish General Hospital, Montreal, Quebec, Canada

and more 1 locations

Uromune in Treating Recurrent Urinary Tract Infections in Women

Phase 2

Terminated

Conditions: Recurrent Uti

Interventions: Biological: Uromune

First Posted Date: 2019-09-20

Last Posted Date: 2024-05-30

Lead Sponsor: Queen's University

Target Recruit Count: 67

Registration Number: NCT04096820

Locations: 🇨🇦
Centre for Advanced Urological Research, Kingston, Ontario, Canada

Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2019-09-17

Last Posted Date: 2024-01-24

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 230

Registration Number: NCT04093167

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 3 locations

Bikram Yoga and Aerobic Exercise for the Treatment of Major Depression

Not Applicable

Completed

Conditions: Depression

Interventions: Other: Bikram Yoga
Other: Aerobic Exercise

First Posted Date: 2019-08-15

Last Posted Date: 2019-08-21

Lead Sponsor: Queen's University

Target Recruit Count: 53

Registration Number: NCT04058080

Evaluating Chronic Pain Self-Management Support With an Opioid De-prescribing Intervention

Not Applicable

Completed

Conditions: Chronic Pain

Interventions: Behavioral: Chronic Pain Self-Management Support

First Posted Date: 2019-03-26

Last Posted Date: 2021-01-12

Lead Sponsor: Queen's University

Target Recruit Count: 24

Registration Number: NCT03890263

Locations: 🇨🇦
Queen's Family Health Team, Belleville, Ontario, Canada

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Phase 2

Recruiting

Conditions: Cancer

Interventions: Drug: Durvalumab
Drug: Prednisone
Drug: Tremelimumab

First Posted Date: 2019-02-20

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 60

Registration Number: NCT03847649

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Windsor Regional Cancer Centre, Windsor, Ontario, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

and more 9 locations

De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Oropharyngeal Cancer

Interventions: Radiation: Radiation
Drug: Cisplatin

First Posted Date: 2019-01-30

Last Posted Date: 2024-07-31

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 103

Registration Number: NCT03822897

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
The Research Institute of the McGill University, Montreal, Quebec, Canada

and more 11 locations

Fasting and Exercise-induced Changes in Human Skeletal Muscle

Not Applicable

Completed

Conditions: Skeletal Muscle Energetics

Interventions: Other: FAST+EX
Other: FAST

First Posted Date: 2019-01-22

Last Posted Date: 2019-05-30

Lead Sponsor: Queen's University

Target Recruit Count: 10

Registration Number: NCT03811717

Locations: 🇨🇦
School of Kinesiology and Health Studies, Kingston, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy